Titration Schedule > Wedding Vows

He can recite the twelve-week uptitration ladder from memory but cannot remember what he promised at the altar.

Filed under Survodutide ·Mazdutide ·Cagrilintide · #stack-life ·#gym-bro ·#cope

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Mazdutide · Incretin Mimetic

The world's first approved dual GLP-1/glucagon receptor agonist, developed by Innovent Biologics (China). Approved in China for obesity and type 2 diabetes. Phase 3 trials showed up to 20.1% weight loss.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

RX: Survodutide · Mazdutide · Cagrilintide
Dosage: 2mg → 4mg → 8mg (weeks 1-12)
Half-life: until the anniversary he forgot
Source: manual
Tags: stack-life , gym-bro , cope
Stamped: 2026-07-08 · Cycle 027
Lot #: LOT-20260708T15:50:12.950Z